Company profile: Intera Oncology
1.1 - Company Overview
Company description
- Provider of hepatic artery infusion (HAI) therapy and liver-directed chemotherapy delivery for colorectal cancer and cholangiocarcinoma patients, offering the Intera 3000 HAI pump, Cerona Therapeutics Floxuridine for Injection, USP, and related products (heparinized saline, saline, bacteriostatic water); acquired Oncology/Neuromodulation Drug Delivery products from Johnson & Johnson.
Products and services
- Hepatic Artery Infusion (HAI) Therapy: A pump-mediated treatment that uses the Intera 3000 to infuse high concentrations of chemotherapy into liver tumors from colorectal cancer or cholangiocarcinoma
- Intera 3000 Hepatic Artery Infusion Pump: An implantable device that delivers chemotherapy directly to the liver for colorectal cancer and cholangiocarcinoma, used in HAI therapy with compatible drug-delivery accessories
- Cerona Therapeutics Floxuridine for Injection, USP: A USP-formulated chemotherapeutic agent indicated for use with the Intera 3000 HAI Pump to enable liver-directed hepatic artery infusion therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Intera Oncology
OncoQuest
HQ: Canada
Website
- Description: Provider of biopharmaceutical products and services, based in Edmonton.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoQuest company profile →
Imvax
HQ: United States
Website
- Description: Provider of patient-specific vaccines and immunotherapies for solid tumors, including IGV-001, a personalized treatment for glioblastoma in Phase 2b trials, and preclinical programs IEC-001 (endometrial), IHC-001 (hepatocellular), IUC-001 (urothelial), and IOC-001 (ovarian). Offers the Goldspire platform to capture a tumor’s full antigen signature for developing personalized immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imvax company profile →
Kairos Pharma
HQ: United States
Website
- Description: Provider of clinical-stage cancer immunotherapies addressing drug resistance: ENV-105 (Endoglin-targeting antibody; Phase I/II for prostate and lung), KROS-201 (activated T cell therapy for glioblastoma), KROS-101 (GITR agonist), KROS-102 (GITR antagonist), KROS-301 (RelA/NF-κB inhibitor), and KROS-401 (IL4/IL13 cyclic peptide for triple-negative breast cancer, with radiation).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kairos Pharma company profile →
Atara Biotherapeutics
HQ: United States
Website
- Description: Provider of off-the-shelf, allogeneic T-cell immunotherapies, conducting clinical studies to evaluate safety and efficacy; offering expanded access to investigational drugs for treatment use; providing educational grants in T-cell immunotherapy; and supplying healthcare providers with information on products and clinical application.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atara Biotherapeutics company profile →
Capintec
HQ: United States
Website
- Description: Provider of calibration and measurement technologies for nuclear medicine applications, offering advanced technology and services with a commitment to continuous quality improvement, including the Captus® 4000e Thyroid Uptake System for measuring thyroid uptake.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Capintec company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Intera Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Intera Oncology
2.2 - Growth funds investing in similar companies to Intera Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Intera Oncology
4.2 - Public trading comparable groups for Intera Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →